EGFR and head and neck cancer: A global phase III clinical trial of NIR-PIT is currently underway for treating inoperable recurrent head and neck cancers, which are targeted based on their overexpressed epidermal growth factor receptor (EGFR) (https://clinicaltrials.gov/ct2/show/NCT03769506).